Glybera, the gene therapy which is the most expensive drug in the world, is to be withdrawn from the market because it has proven to be a commercial failure. Amsterdam-headquartered firm uniQure ...

The company secured approval in Europe for Glybera (alipogene tiparvovec) in 2012. The therapy was approved to treat the ultra-rare disease hereditary lipoprotein lipase deficiency (LPLD), and was ...

Approved last week (November 2) by the European Commission, uniQure’s Glybera utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a ...

The only other gene therapies to have made it to market so far are uniQure’s Glybera’s (alipogene tiparvovec), and GSK’s Strimvelis, but both have only gained EU approval. Glybera is a case ...